NCT04983745View on ClinicalTrials.gov

Niraparib and Dostarlimab in HRD Solid Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

November 29, 2021

Primary Completion Date

August 31, 2024

Study Completion Date

August 31, 2025

Conditions

Homologous Recombination Deficient Solid Tumors

Interventions

DRUG

Combination drug

niraparib and dostarlimab combination

Trial Locations (1)

38138

RECRUITING

West Cancer Center, Germantown

All Listed Sponsors

lead

West Cancer Center

OTHER